<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379aa" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379aa/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379aa/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379aa"><akn:num>379aa</akn:num><akn:heading>Serious adverse event reporting for nonprescription drugs</akn:heading><akn:content><akn:p>§ 379aa. Serious adverse event reporting for nonprescription drugs(a) DefinitionsIn this section:(1) Adverse eventThe term “adverse event” means any health-related event associated with the use of a nonprescription drug that is adverse, including—(A) an event occurring from an overdose of the drug, whether accidental or intentional;

(B) an event occurring from abuse of the drug;

(C) an event occurring from withdrawal from the drug; and

(D) any failure of expected pharmacological action of the drug.


(2) Nonprescription drugThe term “nonprescription drug” means a drug that is—(A) not subject to section 353(b) of this title; and

(B) not subject to approval in an application submitted under section 355 of this title.


(3) Serious adverse eventThe term “serious adverse event” is an adverse event that—(A) results in—(i) death;

(ii) a life-threatening experience;

(iii) inpatient hospitalization;

(iv) a persistent or significant disability or incapacity; or

(v) a congenital anomaly or birth defect; or


(B) requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described under subparagraph (A).


(4) Serious adverse event reportThe term “serious adverse event report” means a report that is required to be submitted to the Secretary under subsection (b).



(b) Reporting requirement(1) In generalThe manufacturer, packer, or distributor whose name (pursuant to section 352(b)(1) of this title) appears on the label of a nonprescription drug marketed in the United States (referred to in this section as the “responsible person”) shall submit to the Secretary any report received of a serious adverse event associated with such drug when used in the United States, accompanied by a copy of the label on or within the retail package of such drug.


(2) RetailerA retailer whose name appears on the label described in paragraph (1) as a distributor may, by agreement, authorize the manufacturer or packer of the nonprescription dru</akn:p></akn:content><akn:subsection eId="subsec_379aa_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_b"><akn:num>(b)</akn:num><akn:heading>Reporting requirement</akn:heading><akn:content><akn:p>(b) Reporting requirement</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_c"><akn:num>(c)</akn:num><akn:heading>Submission of reports</akn:heading><akn:content><akn:p>(c) Submission of reports</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_d"><akn:num>(d)</akn:num><akn:heading>Contents of reports</akn:heading><akn:content><akn:p>(d) Contents of reports Each serious adverse event report under this section shall be submitted to the Secretary using the MedWatch form, which may be modified by the Secretary for nonprescription drugs, and may be accompanied by additional information.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_e"><akn:num>(e)</akn:num><akn:heading>Maintenance and inspection of records</akn:heading><akn:content><akn:p>(e) Maintenance and inspection of records</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_f"><akn:num>(f)</akn:num><akn:heading>Protected information</akn:heading><akn:content><akn:p>(f) Protected information A serious adverse event report submitted to the Secretary under this section, including any new medical information submitted under subsection (c)(2), or an adverse event report voluntarily submitted to the Secretary shall be considered to be—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_g"><akn:num>(g)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(g) Rule of construction The submission of any adverse event report in compliance with this section shall not be construed as an admission that the nonprescription drug involved caused or contributed to the adverse event.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_h"><akn:num>(h)</akn:num><akn:heading>Preemption</akn:heading><akn:content><akn:p>(h) Preemption</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379aa_i"><akn:num>(i)</akn:num><akn:heading>Authorization of appropriations</akn:heading><akn:content><akn:p>(i) Authorization of appropriations There are authorized to be appropriated to carry out this section such sums as may be necessary.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>